542 例卵巢肿瘤中 IMP2 和 IMP3 的全面免疫组织化学分析。

A comprehensive immunohistochemical analysis of IMP2 and IMP3 in 542 cases of ovarian tumors.

机构信息

Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800, Prague 2, Czech Republic.

Department of Pathology, 3rd Faculty of Medicine, Charles University, University Hospital Kralovske Vinohrady, 10034, Prague, Czech Republic.

出版信息

Diagn Pathol. 2023 Feb 6;18(1):15. doi: 10.1186/s13000-023-01300-4.

DOI:10.1186/s13000-023-01300-4

PMID:36740684

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9901072/

Abstract

BACKGROUND

IMP2 and IMP3 are mRNA binding proteins involved in carcinogenesis. We examined a large cohort of ovarian tumors with the aim to assess the value of IMP2 and IMP3 for differential diagnosis, and to assess their prognostic significance.

METHODS

Immunohistochemical analyses with antibodies against IMP2 and IMP3 were performed on 554 primary ovarian tumors including 114 high grade serous carcinomas, 100 low grade serous carcinomas, 124 clear cell carcinomas, 54 endometrioid carcinomas, 34 mucinous carcinomas, 75 mucinous borderline tumors, and 41 serous borderline tumors (micropapillary variant). The associations of overall positivity with clinicopathological characteristics were evaluated using the chi-squared test or Fisher's Exact test.

RESULTS

We found IMP2 expression (in more than 5% of tumor cells) in nearly all cases of all tumor types, so the prognostic meaning could not be analyzed. The positive IMP3 expression (in more than 5% of tumor cells) was most common in mucinous carcinomas (82%) and mucinous borderline tumors (81%), followed by high grade serous (67%) and clear cell carcinomas (67%). The expression was less frequent in endometrioid carcinomas (39%), low grade serous carcinomas (23%), and micropapillary variant of serous borderline tumors (20%). Prognostic significance of IMP3 could be evaluated only in low grade serous carcinomas in the case of relapse-free survival, where negative cases showed better RFS (p = 0.033).

CONCLUSION

Concerning differential diagnosis our results imply that despite the differences in expression in the different ovarian tumor types, the practical value for diagnostic purposes is limited. Contrary to other solid tumors, we did not find prognostic significance of IMP3 in ovarian cancer, with the exception of RFS in low grade serous carcinomas. However, the high expression of IMP2 and IMP3 could be of predictive value in ovarian carcinomas since IMP proteins are potential therapeutical targets.

摘要

背景

IMP2 和 IMP3 是参与致癌作用的 mRNA 结合蛋白。我们检查了大量卵巢肿瘤病例，旨在评估 IMP2 和 IMP3 在鉴别诊断中的价值，并评估其预后意义。

方法

使用针对 IMP2 和 IMP3 的抗体对 554 例原发性卵巢肿瘤（包括 114 例高级别浆液性癌、100 例低级别浆液性癌、124 例透明细胞癌、54 例子宫内膜样癌、34 例黏液性癌、75 例黏液性交界性肿瘤和 41 例浆液性交界性肿瘤（微乳头状变体））进行免疫组织化学分析。使用卡方检验或 Fisher 确切检验评估总阳性与临床病理特征的相关性。

结果

我们发现几乎所有肿瘤类型的病例均存在 IMP2 表达（肿瘤细胞中超过 5%），因此无法分析其预后意义。IMP3 阳性表达（肿瘤细胞中超过 5%）最常见于黏液性癌（82%）和黏液性交界性肿瘤（81%），其次是高级别浆液性癌（67%）和透明细胞癌（67%）。子宫内膜样癌（39%）、低级别浆液性癌（23%）和浆液性交界性肿瘤微乳头状变体（20%）的表达频率较低。仅在无复发生存率方面，低级别浆液性癌中 IMP3 的表达具有预后意义，阴性病例的 RFS 更好（p=0.033）。